Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals has applied to the ASX for quotation of 3,640,347 new ordinary fully paid shares. The newly issued securities, which were previously flagged in an earlier capital transaction notice, are scheduled to be quoted from 13 April 2026, modestly increasing the company’s listed share base and potentially enhancing its trading liquidity.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an Australia-listed biotechnology company focused on pharmaceutical development. The company is involved in creating and commercialising therapeutics, with its ordinary fully paid shares traded on the Australian Securities Exchange under the ticker BOT.
Average Trading Volume: 14,846,451
Technical Sentiment Signal: Sell
Current Market Cap: A$94.79M
See more insights into BOT stock on TipRanks’ Stock Analysis page.